Zymeworks  logo
Zymeworks ZYME
$ 26.86 0.26%

Quarterly report 2022-Q2
added 12-23-2023

report update icon

Zymeworks Balance Sheet 2011-2025 | ZYME

Annual Balance Sheet Zymeworks

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-200 M - - - - -12 M -11.5 M - - - -

Long Term Debt

100 K - - - - 4.42 M - - - - -

Long Term Debt Current

1.31 M 2.71 M 1.28 M - - - - - - - -

Total Non Current Liabilities

- 2.86 M 40 M 33.9 M 866 K 68.4 M 59 K - - - -

Total Current Liabilities

71.9 M 85.7 M 82.6 M 30 M - - - - - - -

Total Liabilities

140 M 128 M 123 M 64 M 15.5 M 85 M 4.91 M - - - -

Deferred Revenue

- 32.9 M - 3.53 M - - - - - - -

Retained Earnings

-683 M -471 M -291 M -145 M -109 M -97.8 M -63.9 M - - - -

Total Assets

389 M 538 M 368 M 244 M 132 M 94 M 23.1 M - - - -

Cash and Cash Equivalents

202 M 242 M 128 M 42.2 M 35.9 M 16.4 M - - - - -

Book Value

249 M 410 M 246 M 180 M 116 M 9 M 18.2 M - - - -

Total Shareholders Equity

249 M 410 M 246 M 180 M 116 M 9 M - - - - -

All numbers in USD currency

Quarterly Balance Sheet Zymeworks

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - 92 K 100 K 105 K 111 K 114 K 122 K 122 K 122 K 122 K 46 K 46 K 46 K 46 K 42 K 42 K 42 K 42 K 4.7 M 4.7 M 4.7 M 344 K - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - 147 M 148 M 140 M 141 M 150 M 113 M 128 M 139 M 116 M 114 M 123 M 123 M 123 M 123 M 64 M 63.9 M 63.9 M 63.9 M 15.5 M 15.5 M 15.5 M 15.5 M - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - 3.53 M 3.53 M 3.53 M 3.53 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - -820 M -756 M -683 M -644 M -583 M -516 M -471 M -433 M -361 M -322 M -291 M -291 M -291 M -291 M -145 M -145 M -145 M -145 M -109 M -109 M -109 M -109 M - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - 369 M 430 M 389 M 420 M 472 M 490 M 538 M 572 M 607 M 637 M 368 M 368 M 368 M 368 M 244 M 244 M 244 M 244 M 132 M 132 M 132 M 132 M - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - 276 M 202 M 253 M 257 M 280 M 242 M 242 M 242 M 242 M 128 M 128 M 128 M 128 M 42.2 M 42.2 M 42.2 M 42.2 M 35.9 M 35.9 M 35.9 M 35.9 M 16.4 M - - - 11.5 M - - - - - - - - - - - - - - - - - - -

Book Value

- - 222 M 282 M 249 M 279 M 321 M 377 M 410 M 432 M 491 M 522 M 246 M 246 M 246 M 246 M 180 M 180 M 180 M 180 M 116 M 116 M 116 M 116 M - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - 222 M 282 M 249 M 279 M 321 M 377 M 410 M 432 M 491 M 522 M 246 M 310 M 334 M 170 M 180 M 180 M 180 M 180 M 116 M 116 M 116 M 116 M 9 M - - - 18.2 M - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Zymeworks , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.79 2.35 % $ 795 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.04 4.83 % $ 235 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.17 4.46 % $ 6.38 M chinaChina
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 0.93 -8.81 % $ 257 K usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 212.81 1.71 % $ 5 B danmarkDanmark
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.1 0.16 % $ 7.46 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioVie BioVie
BIVI
$ 1.27 -3.05 % $ 1.88 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.03 0.95 % $ 27.2 B germanyGermany
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.81 1.36 % $ 1.3 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.48 0.96 % $ 139 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.18 -25.03 % $ 392 M israelIsrael
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.37 2.06 % $ 814 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 591.15 0.02 % $ 44.8 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.53 -0.39 % $ 15.9 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 92.45 0.34 % $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 26.83 0.94 % $ 1.73 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.0 -1.32 % $ 1.48 B britainBritain